Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Abstract

// <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Maria Thomsen1, 2, Christian Kersten3, Halfdan Sorbye4, Eva Skovlund5, Bengt Glimelius6, Per Pfeiffer7, Julia S. Johansen8, Elin H. Kure9, Tone Ikdahl10, Kjell Magne Tveit1, 2, 11, Thoralf Christoffersen12, Tormod Kyrre Guren1, 11 1Department of Oncology, Oslo University Hospital, Oslo, Norway 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway 3Department of Oncology, Southern Hospital Trust, Kristiansand, Norway 4Department of Oncology, Haukeland University Hospital, University of Bergen, Bergen, Norway 5Department of Public Health and General Practice, Norwegian University of Science and Technology, Trondheim, Norway 6Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden 7Department of Oncology, Odense University Hospital, Institute of Clinical Research, University of Southern Denmark, Odense, Denmark 8Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Herlev, Denmark 9Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway 10Akershus University Hospital, Nordbyhagen, Norway 11K.G. Jebsen Colorectal Cancer Research Centre, Oslo University Hospital, Oslo, Norway 12Department of Pharmacology, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway Correspondence to: Maria Thomsen, email: uxthmg@ous-hf.no Keywords: mCRC, IL-6, CRP, prognostic biomarker, survival Received: May 20, 2016 Accepted: September 19, 2016 Published: October 12, 2016